A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Ontology highlight
ABSTRACT: The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.
DISEASE(S): Adenomatous Polyposis Coli,Colorectal Neoplasms,Nasopharyngeal Neoplasms
PROVIDER: 2094034 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA